Zero Human Trials

5-Amino-1MQ

Also known as 5-amino-1-methylquinolinium · NNMT inhibitor

Summary coverage

At a glance

What it is: Oral NNMT inhibitor. Small molecule, not a peptide, and no human trials exist.

Evidence: Practitioner experience onlyHow the tiers workThere are no human trials of 5-Amino-1MQ. A vendor clinical review dated 28 April 2026 concedes as much in its own words: there are essentially no published large-scale human randomised trials. Why this tier

Half-life: Not established in available literature
Routes: Oral
Category: Metabolic
FDA: Not nominated; As of 3 August 2026. What that means
WADA: We do not state a status

Putting 5-Amino-1MQ on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.

Evidence

Why this tier

There are no human trials of 5-Amino-1MQ. A vendor clinical review dated 28 April 2026 concedes as much in its own words: there are essentially no published large-scale human randomised trials. The preclinical basis is mouse work at 20 mg/kg subcutaneously three times daily for 11 days (2018) and 32 mg/kg/day (2024). The dosing on this page is community practice, published because people follow it, not because it has support.

Overview

What it is

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, sold as an oral capsule for fat loss. It is not a peptide and there is no validated injectable form. A targeted search of the 2023–2026 literature returns one paper, about NNMT in bladder-cancer fibroblasts, not about this compound as a weight-loss agent. There are no human trials of any size.

Mechanism

How it works

Nicotinamide N-methyltransferase, NNMT, methylates nicotinamide and is highly expressed in adipose tissue, where its activity is associated with reduced energy expenditure. Inhibiting it is proposed to raise cellular NAD+ availability and shift adipocytes toward burning rather than storing. That reasoning is coherent and it comes entirely from mouse work: 20 mg/kg subcutaneously three times daily for 11 days in a 2018 study, and 32 mg/kg/day in a 2024 one. Nobody has measured what oral dosing does to NNMT activity in a person, which means the mechanism is a hypothesis about humans rather than a finding in them.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.

Community practice · low50 mg
Once daily
Reported starting dose, typically for one to two weeks before any increase. Vendor-tier with no human data behind it.
Community practice · mid100 mg
Daily, split 50 mg morning and 50 mg evening
Vendor-tier.
Community practice · high150 mg
Daily, divided
Vendor-tier. Reported cycling is 8 weeks on and 4 weeks off, which is convention, not evidence.

Phase	Amount	Frequency	Timing	Note
Community practice · low	50 mg	Once daily	Not established in available literature	Reported starting dose, typically for one to two weeks before any increase. Vendor-tier with no human data behind it.
Community practice · mid	100 mg	Daily, split 50 mg morning and 50 mg evening	Not established in available literature	Vendor-tier.
Community practice · high	150 mg	Daily, divided	Not established in available literature	Vendor-tier. Reported cycling is 8 weeks on and 4 weeks off, which is convention, not evidence.

Cycle guidance: Community sources report 8 weeks on and 4 weeks off. There is no study behind that.
Goals: Fat loss

Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.

Not nominatedas of 3 August 2026 · US

Not approved for human use, not scheduled, and absent from FDA’s compounding category lists. It is also not GMP-manufactured when sold commercially and carries no pharmacovigilance, which means nothing that happens to anyone taking it is being counted anywhere.

Primary source

Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.

We do not state a status

Not named on the 2026 Prohibited List. We could not determine a classification and do not state one.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

There is nothing to mix

Not applicable. None of the published routes for this compound take a diluent, so there is no concentration to calculate and no beyond-use window to track.

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Common

Headache in the first weekCommunity-reported.
Mild nauseaCommunity-reported as better with food.

Uncommon

Sleep changes in either directionCommunity-reported.

Rare

Theoretical methylation effectsInhibiting a methyltransferase has theoretical consequences for methyl-group handling. No one has quantified them in a person.

Safety

Contraindications and interactions

Do not use if

Not approved for human use, not GMP-manufactured when sold commercially, and with no pharmacovigilance behind it: any adverse effect goes unrecorded

Interactions

Not established in available literature.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage: An oral capsule. There is no diluent, concentration or beyond-use window. There is also no validated injectable form of this compound, whatever is being sold.
Cost: Not established in available literature

Deep dive

5-Amino-1MQ in full

Limited coverage

5-Amino-1MQ is a small molecule, not a peptide, sold as an oral capsule. There is no validated injectable form, whatever some vendors offer.

The mechanism

Nicotinamide N-methyltransferase, NNMT, methylates nicotinamide, and it is highly expressed in fat tissue where its activity is associated with lower energy expenditure. Inhibit it and the proposal is that cellular NAD+ availability rises and adipocytes shift toward burning rather than storing.

That is a coherent hypothesis and it comes entirely from mice: 20 mg/kg subcutaneously three times daily for 11 days in a 2018 study, 32 mg/kg/day in a 2024 one.

The evidence, stated exactly

There are no human trials. Not small ones, not underpowered ones: none. A targeted search of the 2023 to 2026 literature returns a single paper, and it is about NNMT in bladder-cancer-associated fibroblasts, not about this compound as a weight-loss agent.

A vendor clinical review dated 28 April 2026 concedes the point in its own words: there are essentially no published large-scale human randomised trials.

This is one of the most-searched fat-loss compounds in the market, and its human evidence base is empty.

What people do

Community practice, published here because it is what people follow rather than because it has support: 50 mg once daily to start, held for one to two weeks; 100 mg daily split morning and evening; 150 mg daily divided at the top end. Cycling reported as 8 weeks on and 4 weeks off.

Reported effects: first-week headache, mild nausea that is better with food, sleep changes in both directions. Theoretical concerns about methyl-group handling exist, since you are inhibiting a methyltransferase, and nobody has quantified them in a person.

Not approved for human use, not scheduled, not GMP-manufactured when sold commercially, and with no pharmacovigilance system collecting what happens next.

References

Sources

1
The Peptide Toolkit · 5-Amino-1MQ guide (vendor tier)
Source
2
Peptide Dosing Protocols · 5-Amino-1MQ (vendor tier)
Source

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.